Paper9747868
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
Fisher B and 14 others. J Natl Cancer Inst, 1998. Cited by 4,153 papers, by iCite.
Cite this record
ConductScience Library. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Papers, record 9747868. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9747868
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Hormonal | Major topic |
| Breast Neoplasms | Major topic |
| Estrogen Antagonists | Major topic |
| Tamoxifen | Major topic |
| Adult | |
| Cause of Death | |
| Female | |
| Humans | |
| Middle Aged | |
| Neoplasm Invasiveness | |
| Odds Ratio | |
| Quality of Life | |
| Risk | |
| Risk Factors | |
| Treatment Outcome |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| U10-CA-37377 | NCI NIH HHS | United States | U10CA037377 | PubMed and NIH | NIH RePORTER |
| U10-CA-69974 | NCI NIH HHS | United States | U10CA069974 | PubMed and NIH | NIH RePORTER |
Trials7
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00001837 | Effects of Raloxifene on the Uterus and Ovaries of Premenopausal Patients | Background | ClinicalTrials.gov | |
| NCT00073073 | Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer | Background | ClinicalTrials.gov | |
| NCT00092950 | Exercise in Women at Risk for Breast Cancer | Background | ClinicalTrials.gov | |
| NCT00603967 | Effect of Aromatase Inhibitors on Bones and Genes | Background | ClinicalTrials.gov | |
| NCT02394496 | Overcoming Endocrine Resistance in Metastatic Breast Cancer | Background | ClinicalTrials.gov | |
| NCT02936999 | Vitamin D Supplementation in Women With DCIS and/or LCIS | Background | ClinicalTrials.gov | |
| NCT03112031 | Treatment With Tamoxifen in Cryptococcal Meningitis | Background | ClinicalTrials.gov |
Comments and corrections7
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 9923863 | Re: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. | https://conductscience.org/library/papers/9923863 | PubMed |
| Comment in | 10218518 | Re: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. | https://conductscience.org/library/papers/10218518 | PubMed |
| Comment in | 10772691 | Re: tamoxifen prevention of breast cancer: an instance of the fingerpost. | https://conductscience.org/library/papers/10772691 | PubMed |
| Comment in | 10793117 | Re: weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. | https://conductscience.org/library/papers/10793117 | PubMed |
| Comment in | 10841836 | Re: Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors. | https://conductscience.org/library/papers/10841836 | PubMed |
| Comment in | 11562395 | Re: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. | https://conductscience.org/library/papers/11562395 | PubMed |
| Comment in | 21881041 | Do all patients with breast cancer require systemic adjuvant therapy? | https://conductscience.org/library/papers/21881041 | PubMed |
Cited by1,172
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4,153 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42868199 | Estradiol-associated extracellular signaling in the human breast in vivo identifies mast cells as tumor-supportive stromal mediators. | Oncoimmunology | 2026 | https://conductscience.org/library/papers/42868199 | PubMed |
| 42657161 | Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions. | Front Oncol | 2026 | https://conductscience.org/library/papers/42657161 | PubMed |
| 42593556 | Understanding patient perspectives on breast cancer risk: a qualitative study to inform genetic testing communication in the primary care setting. | J Community Genet | 2026 | https://conductscience.org/library/papers/42593556 | PubMed |
| 42499015 | Recent Advances in Genetic Testing and Clinical Management of Hereditary Breast and Ovarian Cancer (HBOC) in India. | Cancer Med | 2026 | https://conductscience.org/library/papers/42499015 | PubMed |
| 42482767 | Identification and management of genetic susceptibility to cancer: UK perspective. | BMJ Oncol | 2026 | https://conductscience.org/library/papers/42482767 | PubMed |
| 42232584 | Rebalancing immunity: The emerging role of selective estrogen receptor modulators in immunity and autoimmunity. | Curr Trends Immunol | 2025 | https://conductscience.org/library/papers/42232584 | PubMed |
| 42218536 | Compact breast parenchyma: imaging and transcriptomic correlates. | J Transl Med | 2026 | https://conductscience.org/library/papers/42218536 | PubMed |
| 42168229 | Women's preferences for breast cancer risk-reducing medications: a discrete choice experiment study. | NPJ Breast Cancer | 2026 | https://conductscience.org/library/papers/42168229 | PubMed |
| 41927957 | Reply to "Beyond Uptake Aligning Low-Dose Tamoxifen Adherence with Absolute Breast Cancer Risk," by Hu, Zhiping et al. | Ann Surg Oncol | 2026 | https://conductscience.org/library/papers/41927957 | PubMed |
| 41918186 | Clinical Outcomes of Lobular Carcinoma In Situ: Risk of Invasive Cancer Development. | J Breast Cancer | 2026 | https://conductscience.org/library/papers/41918186 | PubMed |
| 41684590 | Endocrine regimen and early subclinical atherosclerosis in premenopausal HR+/HER2- breast cancer: real-world evidence and regimen-dependent effects of Sanhuang Decoction. | Front Oncol | 2026 | https://conductscience.org/library/papers/41684590 | PubMed |
| 41681861 | Cancer Prevention Clinical Trials: Advances and Challenges. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41681861 | PubMed |
| 41654661 | Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose Tamoxifen. | Ann Surg Oncol | 2026 | https://conductscience.org/library/papers/41654661 | PubMed |
| 41510186 | Breast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/41510186 | PubMed |
| 41468356 | Factors Associated with Low-Dose Tamoxifen Use among Women with Atypical Hyperplasia or Lobular or Ductal Carcinoma In Situ. | Cancer Prev Res (Phila) | 2026 | https://conductscience.org/library/papers/41468356 | PubMed |
| 41400398 | Tamoxifen inhibits histidine kinases of M. tuberculosis two-component signaling systems. | Microbiol Spectr | 2026 | https://conductscience.org/library/papers/41400398 | PubMed |
| 41379146 | Interventions to improve adherence to oral endocrine therapy for prevention or treatment of breast cancer in Black women of low socioeconomic status. | Support Care Cancer | 2025 | https://conductscience.org/library/papers/41379146 | PubMed |
| 41364346 | Overview of ocular toxicities associated with breast cancer therapies. | Breast Cancer Res Treat | 2025 | https://conductscience.org/library/papers/41364346 | PubMed |
| 41300964 | Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41300964 | PubMed |
| 41253392 | [Fertility management in breast cancer patients: current strategies and research advances]. | Zhejiang Da Xue Xue Bao Yi Xue Ban | 2025 | https://conductscience.org/library/papers/41253392 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9747868
GET https://conductscience.org/api/papers/v1/9747868/cited_by?page=2